NCT05153408 - (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 13, 2022

Primary Completion Date

December 9, 2022

Study Completion Date

December 9, 2022

Conditions

Lung NeoplasmCarcinoma, Non-Small-Cell LungRespiratory Tract NeoplasmsNeoplasmsNeoplasms by SiteLung DiseasesRespiratory Tract DiseasesCarcinoma, BronchogenicBronchial NeoplasmsAdenocarcinomaCarcinomaNeoplasms by Histologic TypeNeoplasms, Nerve TissueEGFR C797SEGFR C797AEGFR L858REGFR Exon 19 DeletionEGFR Gene MutationEGF-R Positive Non-Small Cell Lung CancerEGFR Mutation Resulting in Tyrosine Kinase Inhibitor ResistanceEGFR Activating MutationThoracic NeoplasmsAntineoplastic AgentsProtein Kinase InhibitorsEGFR C797GEGFR C797XNon Small Cell Lung Cancer

Interventions

DRUG

BLU-701

BLU-701 for oral administration

DRUG

osimertinib

Osimertinib tablets for oral administration

DRUG

carboplatin

IV infusion of carboplatin

DRUG

pemetrexed

IV infusion of pemetrexed

Trial Locations (7)

10016

New York University (NYU) Langone Medical Center, New York

10021

Memorial Sloan Kettering Cancer Center, New York

22031

NEXT Virginia, Fairfax

37203

Sarah Cannon Research Institute, Nashville

48202

Henry Ford Hospital, Detroit

98109

Seattle Cancer Care Alliance, Seattle

02215

Dana-Farber Cancer Institute, Boston